Caution with the use of dexamethasone in patients with COVID-19 in its initial phases
Copyright © 2021 Elsevier España, S.L.U. and Sociedad Española de Medicina Interna (SEMI). All rights reserved..
INTRODUCTION: The effect of dexamethasone in the initial phase of infection by SARS-CoV-2 and its influence on COVID-19 is not well defined. We describe clinical-radiological characteristics, the cytokine storm parameters, and the clinical evolution of a series of patients treated with dexamethasone in the disease's initial phase.
METHOD: A study of 8 patients who received dexamethasone before the development of COVID-19. We evaluate clinical variables, imaging tests, cytokine release parameters, treatment used and patient evolution.
RESULTS: All patients received a 6 mg/day dose with a mean duration of 4.5 days before admission. High resolution computed tomography (HRCT) revealed that most of them presented a severe extension; most patients had a slightly elevated level of cytokine release parameters. Three patients required high-flow oxygen therapy due to respiratory failure; none required orotracheal intubation or died.
CONCLUSION: Dexamethasone in the early stages of SARS-CoV-2 infection appears to be associated with severe COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:221 |
|---|---|
| Enthalten in: |
Revista clinica espanola - 221(2021), 10 vom: 22. Dez., Seite 592-595 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Callejas Rubio, J L [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
7S5I7G3JQL |
|---|
| Anmerkungen: |
Date Completed 10.12.2021 Date Revised 21.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.rceng.2021.02.005 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM331051400 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM331051400 | ||
| 003 | DE-627 | ||
| 005 | 20231225212621.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.rceng.2021.02.005 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1103.xml |
| 035 | |a (DE-627)NLM331051400 | ||
| 035 | |a (NLM)34563488 | ||
| 035 | |a (PII)S2254-8874(21)00156-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Callejas Rubio, J L |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Caution with the use of dexamethasone in patients with COVID-19 in its initial phases |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.12.2021 | ||
| 500 | |a Date Revised 21.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Elsevier España, S.L.U. and Sociedad Española de Medicina Interna (SEMI). All rights reserved. | ||
| 520 | |a INTRODUCTION: The effect of dexamethasone in the initial phase of infection by SARS-CoV-2 and its influence on COVID-19 is not well defined. We describe clinical-radiological characteristics, the cytokine storm parameters, and the clinical evolution of a series of patients treated with dexamethasone in the disease's initial phase | ||
| 520 | |a METHOD: A study of 8 patients who received dexamethasone before the development of COVID-19. We evaluate clinical variables, imaging tests, cytokine release parameters, treatment used and patient evolution | ||
| 520 | |a RESULTS: All patients received a 6 mg/day dose with a mean duration of 4.5 days before admission. High resolution computed tomography (HRCT) revealed that most of them presented a severe extension; most patients had a slightly elevated level of cytokine release parameters. Three patients required high-flow oxygen therapy due to respiratory failure; none required orotracheal intubation or died | ||
| 520 | |a CONCLUSION: Dexamethasone in the early stages of SARS-CoV-2 infection appears to be associated with severe COVID-19 | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Cytokine storm | |
| 650 | 4 | |a Dexametasona | |
| 650 | 4 | |a Dexamethasone | |
| 650 | 4 | |a Síndrome de tormenta de citoquinas | |
| 650 | 7 | |a Dexamethasone |2 NLM | |
| 650 | 7 | |a 7S5I7G3JQL |2 NLM | |
| 700 | 1 | |a Aomar Millan, I |e verfasserin |4 aut | |
| 700 | 1 | |a Moreno-Higueras, M |e verfasserin |4 aut | |
| 700 | 1 | |a Martín Ripoll, L |e verfasserin |4 aut | |
| 700 | 1 | |a Yuste Osorio, E |e verfasserin |4 aut | |
| 700 | 1 | |a Ríos-Fernández, R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Revista clinica espanola |d 2013 |g 221(2021), 10 vom: 22. Dez., Seite 592-595 |w (DE-627)NLM21591063X |x 2254-8874 |7 nnns |
| 773 | 1 | 8 | |g volume:221 |g year:2021 |g number:10 |g day:22 |g month:12 |g pages:592-595 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.rceng.2021.02.005 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 221 |j 2021 |e 10 |b 22 |c 12 |h 592-595 | ||